Skip to content
Search

Latest Stories

Insys founder Kapoor jailed for 66 months over scheme to boost opioid sales

John Kapoor, the founder of Insys Therapeutics Inc, on Thursday, was sentenced to 66 months in prison for his role in a bribery and fraud scheme that contributed to the U.S. opioid crisis.


Kapoor, 76, is now the highest-ranking pharmaceutical executive to be sentenced in a case linked to the opioid crisis. His was the harshest sentence in a case in which several former Insys executives will go to prison.

Forfeiture and restitution in Kapoor's case still need to be determined. Government prosecutors are asking for about $113 million (£86.3 million) in forfeiture from a man who grew up poor in India, but became a billionaire before founding Insys.

During a hearing that lasted nearly two hours, U.S. prosecutors asked U.S. District Court Judge Allison D. Burroughs to sentence Kapoor to 15 years in prison. Some victims also asked her to give Kapoor a maximum penalty.

Victims told the judge they were prescribed a highly addictive opiate that they did not need. They described losing their teeth and being unable to put two thoughts together as they lived in a haze of addiction. One victim told the judge Kapoor should be treated as a drug trafficker.

Burroughs said her lesser sentence took into account his central role in the crime, his many good works as a philanthropist and his age.

Nevertheless, Kapoor is due to serve significantly more prison time than other former senior Insys executives convicted in the bribery and fraud scheme.

On Wednesday, former Insys Chief Executive Michael Babich, 43, was sentenced to 30 months in prison. Babich last year pleaded guilty to conspiracy to commit mail fraud and wire fraud and agreed to cooperate with the government.

Over several days of testimony, Babich had described the inner workings of the conspiracy in detail. The trial resulted in the conviction of Kapoor, as well as the company's vice president of managed markets, Michael Gurry, national director of sales Richard Simon, and two Insys regional sales directors, Joseph Rowan and Sunrise Lee.

Subsys, the company's fentanyl-based medication, was approved to treat intense pain in cancer patients.

But Babich and others would identify high prescribers of opioid treatments and pay bribes or kickbacks to get them to broaden Subsys uses, increasing the number of new prescriptions, as well as dosage prescribed and units sold.

Assistant U.S. Attorney Nathaniel Yeager described Kapoor as the linchpin of the scheme.

"It was a top-down conspiracy run by John Kapoor," Yeager told the judge.

Burroughs said she was not convinced Kapoor was the linchpin of the operation but acknowledged he was a central player.

Kapoor, who served as the Chandler, Arizona-based drugmaker's chairman and later chief executive after Babich stepped down, apologized to the victims in the courtroom.

"I am heartbroken by the words of the patients," Kapoor said. "I sincerely apologize to them."

From 1999 to 2017, some 400,000 people died from overdoses involving an opioid, including prescription and illicit drugs, according to U.S. health officials.

(Reuters)

More For You

David Thomas Steps In as NPA’s New Wales Representative
Five NPA members are contesting for the remaining position in England (gettyimages)

NPA board update: David Thomas succeeds Raj Aggarwal OBE

Five NPA members are contesting for the remaining position in England

David Thomas, owner of LT Chemists in Newport, will replace Raj Aggarwal OBE as the next National Pharmacy Association (NPA) board member for Wales, following an uncontested election this month.

Keep ReadingShow less
Public Policy Projects calls for better use of community pharmacy skill mix to improve medicines adherence
Non-adherence to medicines remains a critical issue, with an estimated 30 to 50 per cent of medicines for long-term conditions not taken as prescribed. (gettyimages)

Leverage pharmacy skill mix to improve medicines adherence - report suggests

The report also suggested expanding the community pharmacy contractual framework to enable community pharmacy to deliver medicines reviews

Pharmacy technicians and assistants should be enabled to talk to patients about their medications to improve medicines adherence, a new report has recommended.

Keep ReadingShow less
Pharmacy contract consultation to review medicine margin and reimbursement, says Kinnock

Pharmacy contract consultation to review medicine margin and reimbursement, says Kinnock

Kinnock confirms that an announcement on the 2025/26 GP contract would be made before April 2025

The 2025/26 pharmacy contract consultation will include a review of the medicine margin and reimbursement arrangements, health and care minister Stephen Kinnock has confirmed.

Keep ReadingShow less
NHS expands pharmacogenomics trial to enhance personalised medicine
The NHS is poised to take a bold step towards personalised medicine (gettyimages)

Personalised medicine: NHS expands pharmacogenomics trial across England

With this study, the NHS aims to address barriers to the national implementation of pharmacogenomics, making personalised medicine to become standard practice

A national pharmacogenomics research study is making significant progress towards adopting personalised medicine within the NHS.

Keep ReadingShow less
Integrating clinical pharmacists into general practice significantly reduced medicine costs, opioid prescriptions, and anxiolytic use
The growing presence of clinical pharmacists in GP practices is driving improvements in in quality of prescribing and patient safety (gettyimages)

Clinical pharmacists in GP practices improve prescribing quality, patient safety

Integrating clinical pharmacists into general practice significantly reduced medicine costs, opioid prescriptions, and anxiolytic use

The growing presence of clinical pharmacists in GP practices is driving improvements in in quality of prescribing and patient safety in primary care settings, a new study has revealed.

Keep ReadingShow less